^
Association details:
Biomarker:ALK rearrangement
Cancer:Lung Non-Small Cell Squamous Cancer
Drug Class:ALK inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

ALK-rearranged squamous cell carcinoma of the lung

Published date:
02/09/2021
Excerpt:
A total of 20 cases received an ALK inhibitor as first- or second-line treatment which included 11 with a partial response (PR), four with SD, and five with PD. The DCR and ORR was 75.0% (15/20) and 55.0% (11/20), respectively….Patients with ALK-rearranged SCC obtained clinical benefit from ALK-inhibitor therapy, especially those who were non-smokers and whose tumors had been identified by IHC+/FISH+.
DOI:
10.1111/1759-7714.13818